Compare Abbott Laboratories (ABT) vs Asana Inc. (ASAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Asana Inc. — how do they compare? Abbott Laboratories trades at $111.02 (market cap $187.95B), while Asana Inc. trades at $8.97 (market cap $2.13B). The key difference: Abbott Laboratories is far larger — about 88.2× Asana Inc.'s market cap, and Abbott Laboratories pays a 2.32% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.
| ABT | ASAN | |
|---|---|---|
Market Cap | $187.95B | $2.13B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $15.19 |
52-Week Low | $82.57 | $5.46 |
Enterprise Value | $214.96B | $1.96B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Asana (ASAN) trades at $8.96, down 2.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth continues, reaching $723.88M in 2025, while net losses persist at -$255.54M. Recent Q1 2026 earnings beat expectations, and the company secured FedRAMP authorization and acquired StackAI to enhance AI capabilities, signaling strategic growth initiatives.
The outlook hinges on Asana's path to profitability amid high competition; analyst consensus is mixed with a $10.33 price target. Key risks include sustained losses and competitive pressure from larger tech firms, but AI product adoption and government contracts offer potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →
